Kometer M

Reconnect Labs, Winterthur, Switzerland. Electronic address: michael@reconnect-labs.com.

7 papers · 1 preprint

ArticleAyahuasca

Ayahuasca-inspired DMT/HAR formulation reduces brain differentiation between self and other faces.

Suay D, Aicher HD, Kometer M +11

Europe PMC2025
PreprintAyahuasca

Ayahuasca-Inspired DMT/HAR Formulation Reduces Brain Differentiation Between Self and Other Faces

Suay D, Aicher HD, Kometer M +11

Europe PMC2024
ArticlePsilocybin

Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation.

Singer B, Meling D, Hirsch-Hoffmann M +7

Europe PMC2024
ArticleAyahuasca

Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine.

Dornbierer DA, Marten L, Mueller J +11

Europe PMC2023
ArticlePsychedelics

Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison.

Leptourgos P, Fortier-Davy M, Carhart-Harris R +11

Europe PMC2020
ArticlePsilocybin

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations.

Kometer M, Vollenweider FX

Europe PMC2018
ArticlePsilocybin

Effect of Psilocybin on Empathy and Moral Decision-Making.

Pokorny T, Preller KH, Kometer M +2

Europe PMC2017
ArticlePsilocybin

Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Quednow BB, Kometer M, Geyer MA +1

Europe PMC2012